Orchard Therapeutics achieves 100% survival rate during trial treatment for ADA-SCID
- On February 9, 2019
- By GrowthInvest Admin
Orchard Therapeutics, a commercial-stage biopharmaceutical company, presented their two-year follow-up data in 20 patients from the registrational trial evaluating OTL-101, aimed at treating those with adenosine deaminase deficiency (ADA-SCID). They achieved a 100% Overall Survival and 100% Event Free Survival in Patients Treated with OTL-101; compared to 88% OS and 56% EvFS with Historical HSCT Overall at 24 months
ADA-SCID is a rare, life-threatening, inherited disease caused by mutations in the ADA gene. Patients with ADA-SCID are unable to fight off and frequently succumb to complications from bacterial, viral and fungal infections.
GET IN TOUCH!
MAIL US
enquiries@growthinvest.comCALL US
020 7071 3945FOLLOW US ON
Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.
GrowthInvest is a trading name of EIS Platforms Limited. EIS Platforms Limited (FRN: 694945) is an appointed representative of Sapphire Capital Partners LLP (FRN:565716) which is authorised and regulated by the Financial Conduct Authority in the UK.
All rights reserved 2024 @ growthinvest